MedPath
HSA Product

FANHDI FOR INJECTION 250 iu/vial

Product approved by Health Sciences Authority (SG)

Basic Information

FANHDI FOR INJECTION 250 iu/vial

INJECTION, POWDER, FOR SOLUTION

Regulatory Information

SIN11521P

May 17, 2001

Prescription Only

Therapeutic

INTRAVENOUS

August 10, 2023

June 3, 2025

XB02BD02

Company Information

Active Ingredients

Detailed Information

Contraindications

**Contraindications** Caution is advised in patients with known allergic reactions to constituents of the preparation.

Indication Information

**Therapeutic indications** Fanhdi® is indicated for the prevention and control of bleeding in patients with moderate or severe factor VIII deficiency due to classical haemophilia A.

© Copyright 2025. All Rights Reserved by MedPath